Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M403Revenue $M11.3Net Margin (%)-702.4Z-Score3.3
Enterprise Value $M273EPS $-3.8Operating Margin %-705.8F-Score4
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-702.4Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %-12.7Quick Ratio5.9Cash flow > EarningsY
Price/Sales34.15-y EBITDA Growth Rate %-3.2Current Ratio5.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-50.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-57.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M26.3ROI % (ttm)-67.6Gross Margin Increase y-yN

Gurus Latest Trades with DVAX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
DVAXJohn Burbank 2013-12-31 Sold Out -0.05%$11.1 - $20
($14.6)
$ 15.345%Sold Out0
DVAXJohn Burbank 2013-09-30 Buy $10.6 - $14.3
($12.6)
$ 15.3422%New holding, 63492 sh.6,349
DVAXGeorge Soros 2012-06-30 Sold Out -0.03%$35.5 - $52.1
($42.7)
$ 15.34-64%Sold Out0
DVAXGeorge Soros 2012-03-31 Reduce-0.09%$32.8 - $49.4
($38)
$ 15.34-60%Reduce -62.5%37,500
DVAXGeorge Soros 2011-12-31 Buy 0.14%$18.2 - $33.3
($27.9)
$ 15.34-45%New holding, 1000000 sh.100,000
DVAXGeorge Soros 2011-09-30 Sold Out -0.0026%$18.4 - $31.6
($24.5)
$ 15.34-37%Sold Out0
DVAXGeorge Soros 2011-06-30 Buy $24.6 - $28.1
($26.3)
$ 15.34-42%New holding, 66100 sh.6,610
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

DVAX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


DVAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Gray EddieCEO and Director 2014-08-14Buy2,500$14.92.95view
Phillips Peggy VDirector 2013-10-30Buy9,302$10.842.04view
ORONSKY ARNOLD LDirector 2013-10-30Buy18,605$10.842.04view
KISNER DANIEL LDirector 2013-10-30Buy1,000$10.842.04view
Janssen RobertChief Medical Officer and VP 2013-07-09Sell0$042.04view
Novack David FSenior Vice President 2013-03-25Sell0$042.04view
COFFMAN ROBERTChief Scientific Officer & VP 2012-11-06Sell800$43.1-64.41view
KESSEL MARKDirector 2012-10-16Sell600,000$47.3-67.57view
COFFMAN ROBERTChief Scientific Officer & VP 2012-10-05Sell800$49.4-68.95view
Lew JenniferVP, Finance & PAO 2012-09-14Sell1,875$45.3-66.14view

Press Releases about DVAX :

    Quarterly/Annual Reports about DVAX:

    News about DVAX:

    Articles On GuruFocus.com
    Dynavax Announces Webcast of R&D Day Dec 09 2014 
    Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study Dec 08 2014 
    Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of Coll Nov 28 2014 
    Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) Nov 10 2014 
    Dynavax Reports Third Quarter 2014 Financial Results Nov 05 2014 
    Dynavax Announces Resignation of Dino Dina From Board of Directors Oct 15 2014 
    Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma Oct 15 2014 
    Two Promising Health Care Stocks with Market Capitalizations Under $500 Million Jun 11 2014 
    Top Three Largest Insider Buys of the Past Week Nov 05 2013 
    About to submit BLA Mar 11 2012 

    More From Other Websites
    Dynavax & AstraZeneca Alter Agreement for Asthma Product Dec 09 2014
    Dynavax Announces Webcast of R&D Day Dec 09 2014
    Dynavax Announces Webcast of R&D Day Dec 09 2014
    DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 08 2014
    Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study Dec 08 2014
    Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study Dec 08 2014
    Dynavax Regains TLR 7/9 Inhibitor DV1179 Rights from Glaxo Dec 01 2014
    DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 28 2014
    Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of... Nov 28 2014
    Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of... Nov 28 2014
    Lightning Round: You're playing with fire Nov 21 2014
    DYNAVAX TECHNOLOGIES CORP Financials Nov 14 2014
    Dynavax's Heplisav Phase III Trial Recommended to Continue Nov 11 2014
    DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 10 2014
    Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) Nov 10 2014
    Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) Nov 10 2014
    10-Q for Dynavax Technologies Corp. Nov 07 2014
    Dynavax Announces One-for-Ten Reverse Stock Split Nov 07 2014
    Dynavax Announces One-for-Ten Reverse Stock Split Nov 07 2014
    DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 05 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK